CONSONANCE data of Ocrevus shows benefits in 1-year analysis with multiple sclerosis patients

Treatment with Ocrevus resulted in a majority of patients experiencing no disease progression in a one-year analysis of CONSONANCE, a first-of-its-kind open-label Phase IIIb trial to evaluate the effect of Ocrevus in SPMS and PPMS patients. After one year, 75% of Ocrevus-treated patients with SPMS and PPMS achieved No Evidence of Progression (NEP; no evidence of confirmed disability progression as measured by an increase in Expanded Disability Status Score sustained for at least 24 weeks, and less than 20% worsening of performance on the timed 25-foot walk [T25-FW] and Nine-Hole Peg Test [9-HPT]). NEP is a novel composite endpoint and reflects no evidence of worsening of a person’s physical disability.

Additionally, 59% of Ocrevus-treated patients in the trial achieved No Evidence of Progression or Active Disease (NEPAD; NEP plus no protocol-defined relapses, new and/or enlarging T2 lesions or T1 gadolinium-enhancing lesions) over one year. The analysis also demonstrated the positive effects of Ocrevus on cognition, with 70% of patients having stable or improved cognition over one year, as measured with the Symbol Digit Modalities Test (SDMT). Clinically meaningful improvement (increase of at least 4 points on the SDMT) was observed in 34% of patients treated with Ocrevus and worsening (decrease of at least 4 points) in 30% of patients treated with Ocrevus. After one year of participating in the trial, 75% of patients had one or more adverse events (AEs) and 7% experienced at least one serious AE.

Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity will be a platform presentation at the 74th American Academy of Neurology (AAN) Annual Meeting April 2-7, 2022 in Seattle. CONSONANCE data will be presented virtually at AAN April 24-26, 2022.